title: Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
authors.affiliation: Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. witzig@mayo.edu
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Witzig
authors.forename: Peter T
authors.initials: PT
authors.lastname: Silberstein
authors.forename: Charles L
authors.initials: CL
authors.lastname: Loprinzi
authors.forename: Jeff A
authors.initials: JA
authors.lastname: Sloan
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Novotny
authors.forename: James A
authors.initials: JA
authors.lastname: Mailliard
authors.forename: Kendrith M
authors.initials: KM
authors.lastname: Rowland
authors.forename: Steven R
authors.initials: SR
authors.lastname: Alberts
authors.forename: James E
authors.initials: JE
authors.lastname: Krook
authors.forename: Ralph
authors.initials: R
authors.lastname: Levitt
authors.forename: Roscoe F
authors.initials: RF
authors.lastname: Morton
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000139:chemically induced* / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001803:Blood Transfusion; D001943:Breast Neoplasms / Q000188:drug therapy; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007279:Injections, Subcutaneous; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D010919:Placebos; D011788:Quality of Life; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D006454:Hemoglobins; D010919:Placebos; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa